Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in advanced malignancies with FGF/FGFR alterations
NCT04258527Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2020
- Primary completion
- Jul 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pemigatinib in solid tumor, sponsored by Innovent Biologics. Primary endpoints: Maximum observed plasma concentration, Time to maximum plasma concentration and 1 more. Started Mar 2020; status: completed.
02
Drugs
pemigatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04258527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258527.